ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Debt-to-Equity : -1.48 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals Debt-to-Equity?

ASLAN Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $7.32 Mil. ASLAN Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $19.35 Mil. ASLAN Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-17.97 Mil. ASLAN Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was -1.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ASLAN Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ASLN' s Debt-to-Equity Range Over the Past 10 Years
Min: -43.46 Med: 0.21 Max: 5.95
Current: -1.48

During the past 10 years, the highest Debt-to-Equity Ratio of ASLAN Pharmaceuticals was 5.95. The lowest was -43.46. And the median was 0.21.

ASLN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs ASLN: -1.48

ASLAN Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for ASLAN Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals Debt-to-Equity Chart

ASLAN Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-10.96

-1.84

0.54

4.50

-2.02

ASLAN Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															3.84	5.95	-43.46	-2.02	-1.48

Competitive Comparison of ASLAN Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, ASLAN Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASLAN Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ASLAN Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ASLAN Pharmaceuticals's Debt-to-Equity falls into.

ASLAN Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ASLAN Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.027	+	24.799)	/	-13.287
	=	-2.02

ASLAN Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.316	+	19.35)	/	-17.965
	=	-1.48

ASLAN Pharmaceuticals (NAS:ASLN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ASLAN Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ASLAN Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190

Website

https://www.aslanpharma.com

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.